small molecule

WEGOVY HD

SEMAGLUTIDE

Loss of exclusivityFebruary 2041latest FDA-listed patent expiry

CompanyNOVO NORDISK INC

Drug detail

Brand name	WEGOVY HD
Active ingredient	SEMAGLUTIDE
Strength	7.2MG/0.75ML (7.2MG/0.75ML)
Dosage form	SOLUTION
Route	SUBCUTANEOUS
Modality	Small molecule
FDA approval	March 2026
Marketing status	RX

Listed patents

Patent	Expires	Type
11318191	February 2041	product
12029779	October 2038	use U-4418
12551536	October 2038	use U-4418
11752198	August 2038	product
12214017	August 2038	product
10888605	August 2038	product
9764003	June 2033	use U-4418
8129343	December 2031	substance, product

Regulatory exclusivity

Code	Expires
NS	March 2029

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from NOVO NORDISK INC